SCHEMBL3645463

SCHEMBL3645463

CC(C)(C)CCNC1CCCCC1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 1/20 0.44
KDM4E B2RXH2 3/20 0.40
CXCR4 P61073 5/20 0.39
CXCL12 P48061 1/20 0.39
EPHX1 P07099 1/20 0.38
SSTR3 P32745 1/20 0.38
CYP1A2 P05177 2/20 0.37
CYP2D6 P10635 2/20 0.37
CYP2C19 P33261 2/20 0.37
ALDH1A1 P00352 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
CYP2C9 P11712 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
DPP7 Q9UHL4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13912964 0.98 RAD52 (0.41) RAD52KDM4ECXCR4CXCL12EPHX1
SCHEMBL12156771 0.93 RAD52 (0.37) RAD52KDM4ECXCR4CXCL12EPHX1
SCHEMBL803995 0.88 GNAI3 (0.36) RAD52SSTR3ALDH1A1HRH3
SCHEMBL2632339 0.87 CXCR4 (0.44) RAD52KDM4ECXCR4CXCL12ALDH1A1
SCHEMBL13602652 0.85 CXCR4 (0.43) RAD52KDM4ECXCR4CXCL12ALDH1A1
SCHEMBL19669278 0.84 KDM4E (0.42) RAD52KDM4ECXCR4CXCL12CYP1A2
SCHEMBL25087694 0.83 KDM4E (0.42) RAD52KDM4ECXCR4CXCL12EPHX1
SCHEMBL28831920 0.83 RAD52 (0.42) RAD52KDM4ECXCR4CXCL12CYP1A2
SCHEMBL28831909 0.80 RAD52 (0.39) RAD52KDM4ECXCR4CXCL12CYP1A2
SCHEMBL7893718 0.80 GNAI3 (0.53) RAD52EPHX1SSTR3HRH3SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399297-A1 Novel Glutamine Analogs JACOBIO PHARMACEUTICALS CO., LTD (CN) 2023-12-14 US disclosed
US-20230295111-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF GILEAD SCIENCES, INC. 2023-09-21 US disclosed
WO-2023178181-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2023-09-21 WO disclosed
EP-4245756-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF Gilead Sciences, Inc. (US) 2023-09-20 EP disclosed
EP-2183260-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV IDENIX Pharmaceuticals, Inc. (US) 2010-05-12 EP disclosed
WO-2009032180-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV IDENIX PHARMACEUTICALS, INC. (US) 2009-03-12 WO disclosed
US-4459424-A SECONDARY AMINE, CARBON DISULFIDE, METAL CONTAINING CATALYST AKZONA INCORPORATED (US) 1984-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399297-A1 Novel Glutamine Analogs GLUL, GATD3, GLS RAD52 4103/4885KDM4E 1022/4885CXCR4 3553/4885
US-20230295111-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF IKZF2, IKZF1, IKZF3 RAD52 1783/4885KDM4E 233/4885CXCR4 3644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.